Freebody John, Wegner Eva A, Rossleigh Monica A
John Freebody, Eva A Wegner, Monica A Rossleigh, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children's Hospitals, Randwick, NSW 2031, Australia.
World J Radiol. 2014 Oct 28;6(10):741-55. doi: 10.4329/wjr.v6.i10.741.
Positron emission tomography (PET) is a minimally invasive technique which has been well validated for the diagnosis, staging, monitoring of response to therapy, and disease surveillance of adult oncology patients. Traditionally the value of PET and PET/computed tomography (CT) hybrid imaging has been less clearly defined for paediatric oncology. However recent evidence has emerged regarding the diagnostic utility of these modalities, and they are becoming increasingly important tools in the evaluation and monitoring of children with known or suspected malignant disease. Important indications for 2-deoxy-2-((18)F)fluoro-D-glucose (FDG) PET in paediatric oncology include lymphoma, brain tumours, sarcoma, neuroblastoma, Langerhans cell histiocytosis, urogenital tumours and neurofibromatosis type I. This article aims to review current evidence for the use of FDG PET and PET/CT in these indications. Attention will also be given to technical and logistical issues, the description of common imaging pitfalls, and dosimetric concerns as they relate to paediatric oncology.
正电子发射断层扫描（PET）是一种微创技术，已在成人肿瘤患者的诊断、分期、治疗反应监测和疾病监测方面得到充分验证。传统上，PET和PET/计算机断层扫描（CT）混合成像在儿科肿瘤学中的价值尚不明确。然而，最近出现了关于这些检查方式诊断效用的证据，它们正日益成为评估和监测已知或疑似恶性疾病儿童的重要工具。2-脱氧-2-（（18）F）氟-D-葡萄糖（FDG）PET在儿科肿瘤学中的重要适应证包括淋巴瘤、脑肿瘤、肉瘤、神经母细胞瘤、朗格汉斯细胞组织细胞增多症、泌尿生殖系统肿瘤和I型神经纤维瘤病。本文旨在综述FDG PET和PET/CT在这些适应证中的应用现状。还将关注技术和后勤问题、常见成像陷阱的描述以及与儿科肿瘤学相关的剂量学问题。
